Inhibition of expression of the multidrug resistance-associated P- glycoprotein by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides

Molecular Pharmacology

Volumn 50, Issue 4, 1996, Pages 808-819

  Alahari, S K ^a   Dean, N M ^b   Fisher, M H ^a   Delong, R ^a   Manoharan, M ^b   Tivel, K L ^b   Juliano, R L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GLYCOPROTEIN P; PHOSPHOROTHIOIC ACID;

ARTICLE; CHOLESTEROL METABOLISM; ENZYME STABILITY; ENZYME SUBSTRATE; FIBROBLAST; FLOW CYTOMETRY; GENE SEQUENCE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; START CODON; TRANSLATION INITIATION;

3T3 CELLS; ANIMALS; BASE SEQUENCE; CHOLESTEROL; DRUG RESISTANCE, MULTIPLE; HUMANS; INTRACELLULAR FLUID; MICE; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES, ANTISENSE; P-GLYCOPROTEIN; PHENOTYPE; RHODAMINE 123; RHODAMINES; RIBONUCLEASE H, CALF THYMUS; RNA, MESSENGER; THIONUCLEOTIDES; TIME FACTORS;

EID: 0029966767     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Helene, C., and J. J. Toulme. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta 1049: 99-125 (1990).
2. Wagner, R. W. Gene inhibition using antisense oligodeoxynucleotides. Nature (Lond.) 372:333-335 (1994).
3. Stein, C. A., and Y.-C. Cheng. Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science (Washington D. C.) 261:1004-1011 (1993).
4. Cook, D. P. Medicinal chemistry of antisense oligonucleotides-future opportunities. Anti-Cancer Drug Design 6:585-607 (1991).
5. Crooke, S. T. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32:329-376 (1992).
6. Cohen, J. S. Designing antisense oligonucleotides as pharmaceutical agents. Trends Pharmacol. Sci. 10:435-437 (1989).
7. Akhtar, S., and R. L. Juliano. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. 2:139-143 (1992).
8. Shoji, Y., A. Saghir, A. Periasamy, B. Herman, and R. L. Juliano. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res. 19:5543-5550 (1991).
9. Leonetti, J. P., N. Mechti, G. Degols, C. Gagnor, and B. LeBleu. Intracellular distribution of microinjected antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 88:2702-2706 (1991).
10. Feigner, P. L., and G. M. Ringold. Cationic liposome mediated transfection. Nature (Lond.) 337:387-88, 1989.
11. Bennett, C. F., M. Y. Chiang, H. Chan, J. E. Shoemaker, and C. K. Mirabelli. Cationic lipids enhance cellular uptake and activity of phosphorothioate oligonucleotides. Mol. Pharmacol. 41:1023-1033 (1992).
12. Walder, R. Y., and J. A. Walder. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA 85: 5011-5015 (1988).
13. Kulka, M., C. C. Smith, L. Aurelian, R. Fishelevich, K. Meade, P. Miller, and P. O. Ts'o. Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4. Proc. Natl. Acad. Sci. USA 86:6868-6872 (1989).
14. Boiziau, C., R. Kurfurst, C. Cazenave, V. Roig, N. T. Thuong, and J. J. Toulme. Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism. Nucleic Acids Res. 19:1113-1119 (1991).
15. Zon, G., and T. G. Geiser. Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions. Anti-Cancer Drug Des. 6:539-568 (1991).
16. Milligan, J. F., M. D. Matteucci, and J. C. Martin. Current concepts in antisense drug design. J. Med. Chem. 36:1923-1937 (1993).
17. Eckstein, F. Nucleoside phosphorothioates. Annu. Rev. Biochem. 54:367-402 (1985).
18. Chaing, M. Y., H. Cahn, M. A. Zounes, S. M. Freier, W. F. Lima, and C. F. Bennet. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266:18162-18171 (1991).
19. Dean, N. M., R. McKay, T. P. Condon, and C. F. Bennett. Inhibition of protein kinase C-a expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. 269:16416-16420 (1994).
20. Monia, B. P., J. F. Johnston, D. J. Ecker, M. A. Zounes, W. F. Lima, and S. M. Freier. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem. 267:19954-19962 (1992).
21. Saison-Behmoaras, T., B. Tocque, I. Rey, M. Chassignol, N. T. Thuong, and C. Helene. Short modified antisense oligonucleotides directed against Haras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J. 10:1111-1118 (1991).
22. Szczylik, C., T. Skorski, N. C. Nicolaides, L. Manzella, L. Malaguarnera, D. Venturelli, A. Gewirtz, and B. Calabretta. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science (Washington D. C.) 258:562-565 (1991).
23. Citro, G., D. Perrotti, C. Cucco, I. D'Agnano, A. Sacchi, G. Zupi, and B. Calabretta. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 89:7031-7035 (1992).
24. Cotter, F. E., P. Johnson, P. Hall, C. Pocock, N. Al Mahdi, J. K. Cowell, and G. Morgan. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9:3049-3056 (1994).
25. Ensoli, B., P. Markham, V. Kao, G. Barillari, V. Fiorelli, R. Gendelman, and M. Raffeld. Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. J. Clin. Invest. 94:1736-1746 (1994).
26. Higgins, K. A., J. R. Perez, A. Coleman, K. Dorshkind, A. A. McComas, U. M. Sarimento, C. A. Rosen, and R. Narayanan. Antisense inhibition of the p65 subunit of NK-κB blocks tumorigenicity and causes tumor regression. Proc. Natl. Acad. Sci. USA 90:9901-9905 (1993).
27. Dean, N. M., and R. McKay. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 91:117662-11766 (1994).
28. Schwab, G., C. Chavany, I. Duroux, G. Goubin, J. LeBeau, C. Helene, and T. Saison-Behmoaras. Antisense oligonucleotides adsorbed to polyalkycyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc. Natl. Acad. Sci. USA 91:10460-10464 (1994).
29. Listerud, M., A. B. Brussaard, P. Devay, D. R. Colman, and L. W. Role. Functional contribution of neuronal AChR subunits revealed by antisense oligonucleotides. Science (Washington. D. C.) 254:1518-1521 (1991).
30. Knecht, D., and W. F. Loomis. Antisense RNA inactivation of myosin heavy chain gene expression in Dictyostelium discoideum. Science (Washington D. C.) 236:1081-1086 (1987).
31. Vaughn, J. P, J. R. Marks, and J. D. Iglehart. A study of antisense downregulation of the erbB-2 receptor. Proc. Annu. Meet. Am. Assoc. Cancer Res. 36:A3069 (1995).
32. Wolley, P. V., and K. D. Tew (eds.). Mechanisms of Drug Resistance in Neoplastic Cells. Academic Press, New York (1988).
33. Bradley, G., and V. Ling. P-Glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev. 13:223-233 (1994).
34. Licht, T., I. Pastan, M. Gottesman, and F. Herrmann. P-Glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells. Ann Hematol. 69:159-171 (1994).
35. Roninson, I. B. The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem. Pharmacol. 43:95-102 (1992).
36. Kajiji, S., J. A. Dreslin, K. Grizzuti, and P. Gros. Structurally distinct MDR modulators show specific patterns of reversal against P-glycoproteins bearing unique mutations at serine939/941. Biochem. 33:5041-5048 (1994).
37. Chabner, B. A., and W. Wilson. Reversal of multidrug resistance. J. Clin. Oncol. 9:4-6 (1991).
38. Kiehntopf, M., M. A. Brach, T. Licht, S. Petschauer, L. Karawajew, C. Kirschning, and F. Herrmann. Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. EMBO J. 13:4645-4652 (1994).
39. Kobayashi, H., T. Dorai, J. F. Holland, and T. Ohnuma. Reversal of dug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res. 54:1271-1275 (1994).
40. Scanlon, K. J., H. Ishida, and M. Kashani-Sabet. Ribozyme-mediated reversal of the multidrug resistant phenotype. Proc. Natl. Acad. Sci. USA 91:11123-11127 (1994).
41. Jaroszewski, J. W., O. Kaplan, J. L. Syi, M. Sehested, P. J. Faustino, and J. S. Cohen. Concerning antisense inhibition of the multiple drug resistance gene. Cancer Commun. 2:287-294 (1990).
42. Rivoltini, L, M. P. Colombo, R. Supino, D. Ballinari, T. Tsuruo, and G. Parmiani. Modulation of multidrug resistance by verapamil or MDR1 antisense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. Int. J. Cancer 46:727-732 (1990).
43. Corrias, M. V., and G. P. Tonini. An oligomer complementary to the 5′ end region of MDR1 gene decreases resistance to doxorubicin of human adenocarcinoma-resistant cells. Anticancer Res. 12:1431-1438 (1992).
44. Efferth, T., and M. Volm. Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells. Oncology 50:303-308 (1993).
45. Zhang, J. T., and V. Ling. Study of membrane orientation and glycosylation of extracellular loops of mouse P-glycoprotein by in vitro translation. J. Biol. Chem. 266:18224-18232 (1991).
46. Kane, S. E., D. H. Reinhard, C. M. Fordis, I. Pastan, and M. M. Gottesman. A new vector using the human multidrug resistance gene as a selectable marker enables overexpression of foreign genes in eukaryotic cells. Gene 84:439-446 (1989).
47. MacKellar, C., D. Graham, D. W. Will, S. Burgess, and T. Brown. Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups. Nucleic Acids Res. 20:3411-3417 (1992).
48. Manoharan, M., K. L. Tivel, and P. D. Cook. Lipidic nucleic acids. Tetrahedron Lett. 36:3651 (1995).
49. Alahari, S. K., H. Schmidt, and N. F. Kaufer. The fission yeast prp4+ gene involved in pre-mRNA splicing codes for a ser/threo kinase and is essential for growth. Nucleic Acids Res. 21:4079-4083 (1993).
50. Ishida, Y. Ohtsu, T., H. Hamada, Y. Sugimoto, K. Tobinai, K. Minato, T. Tsuruo, and M. Shimoyama. Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK 16. Jpn. J. Cancer Res. 80:1006-1013 (1989).
51. Twentyman, P. R., T. Rhodes, and S. Rayner. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein mediated and MRP-associated multidrug resistance phenotypes. Eur. J. Cancer 30: 1360-1369 (1994).
52. Richert, N. D., L. Aldwin, D. Nilecki, M. M. Gottesman, and I. Pastan. Stability and covalent modification of P-glycoprotein in multidrug resistant KB cells. Biochemistry 28:7607-7613 (1988).
53. Krieg, A. M., J. Tonkinson, S. Matson, Q. Zhao, M. Saxon, L. M. Zhang, U. Bhanja, L. Yakubov, and C. A. Stein. Modification of antisense phosphodiester oligodeoxynucleotides by a 5′ cholesterol moiety increases cellular association and improves efficacy. Proc. Natl. Acad. Sci. USA 90:1048-1052 (1993).
54. Letsinger, R. L., G. R. Zhang, D. K. Sun, T. Ikeuchi, and P. S. Sarin. Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc. Natl. Acad. Sci. USA 86:6553-6556 (1989).
55. Moulds, C., J. G. Lewis, B. C. Froehler, D. Grant, T. Huang, J. F. Milligan, M. D. Matteucci, and R. W. Wagner. Site and mechanism of antisense inhibition of C-5 propyne oligonucleotides. Biochemistry 34:5044-5053 (1995).
56. Plank, C., B. Oberhauser, K. Mechtler, C. Koch, and E. Wagner. The influence of endosome disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J. Biol. Chem. 269:12918-12924 (1994).
57. Delfontaine, P., X. P. Meng, L. Ku, and J. Du. Regulation of vascular smooth muscle cell insulin-like growth factor I receptors by phosphorothioate antisense oligonucleotides. J. Biol. Chem. 270:14383-14388 (1995).
58. Bavisotto, L., K. Kaushansky, N. Lin, and R. Hromas. Antisense oligonucleotides from stage specific zinc finger gene MZF-1 inhibit granulopoiesis in vitro. J. Exp. Med. 174:1097-1101 (1991).